Testing for Mycoplasma genitalium in pelvic inflammatory disease: A clinical audit

Aust N Z J Obstet Gynaecol. 2022 Dec;62(6):826-829. doi: 10.1111/ajo.13609. Epub 2022 Sep 11.

Abstract

The records of women attending Gold Coast health hospital sites were retrospectively analysed to determine if women diagnosed with pelvic inflammatory disease (PID) were being tested for Mycoplasma genitalium (MG). Only 11.4% of 299 women were tested for MG despite 74.2% being tested for Chlamydia trichomonas (CT) and Neisseria gonorrhoeae (NG). Only 9% of the women were treated with antibiotics which would treat macrolide-sensitive MG infection. Increasing education and awareness of MG and utilising reflex macrolide testing for MG will help direct effective antibiotic therapy and prevent the long-term sequalae of PID.

Keywords: Clinical audit; Macrolide resistance; Mycoplasma Genitalium; Pelvic inflammatory disease; Sexually transmitted diseases.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Chlamydia Infections* / diagnosis
  • Chlamydia Infections* / drug therapy
  • Chlamydia trachomatis
  • Clinical Audit
  • Female
  • Humans
  • Macrolides
  • Mycoplasma genitalium*
  • Pelvic Inflammatory Disease* / diagnosis
  • Pelvic Inflammatory Disease* / drug therapy
  • Retrospective Studies

Substances

  • Macrolides
  • Anti-Bacterial Agents